167 results
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
15 May 24
Adaptimmune Reports Q1 2024 Financial and Business Updates
7:39am
in the three months ended March 31, 2024 increased in employee-related costs and additional costs associated with lease properties following
8-K
EX-10.1
6rsqc1kj
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
8-K
9d1nb41 v7
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
S-8
cr53m2
30 Nov 23
Registration of securities for employees
4:16pm
S-8
h7fdpwn5jw 0hxm3
30 Nov 23
Registration of securities for employees
4:16pm
S-8
EX-5.1
3nqsuk0
30 Nov 23
Registration of securities for employees
4:16pm
S-8 POS
dbn6mqqhqrfcyf9kj
29 Jun 23
Registration of securities for employees (post-effective amendment)
4:54pm
S-8 POS
h39n2tm a9e
29 Jun 23
Registration of securities for employees (post-effective amendment)
4:48pm
8-K
EX-10.1
9g5mpypghcz
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
8-K
fausjjrya92tb7g54n2b
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
8-K
EX-10.2
vjm59j3
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
8-K
EX-10.2
ecu5h
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.3
ervmqm78xq3 4s9gp7uf
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.4
wip1s5cpifq07
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm